Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloEx Exosomes in Congenital Myasthenic Syndrome
NCT07226726Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloEx in congenital myasthenic syndrome (CMS), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Oxygen Saturation at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
AlloEx
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on NCT07226726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226726.